You raised a good point - their business model is a mixed of everything. I think the value I see from this annoucement is that EMD can leverage its current business model (using other products to provide clinical care in their clinics) to the research and development phase. A lot of the R&D requires real-world clinical information and the feasibility data. Often the R&D in the lab is mainly theoretical, and it is very hard to translate that result into a real-world settings. So I guess once they have enough clinical data they collected in the clinics, this will faciliate the process in pivotting the development of clinical trials and ensuring their products meet the guidelines and policies in place.
- Forums
- ASX - By Stock
- Ann: Emyria secures clinical-grade MDMA supply for Aust patients
EMD
emyria limited
Add to My Watchlist
5.13%
!
4.1¢

You raised a good point - their business model is a mixed of...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
4.1¢ |
Change
0.002(5.13%) |
Mkt cap ! $25.06M |
Open | High | Low | Value | Volume |
3.8¢ | 4.1¢ | 3.8¢ | $61.46K | 1.550M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 90000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1 | 0.041 |
2 | 266133 | 0.040 |
2 | 358696 | 0.039 |
4 | 585597 | 0.037 |
3 | 392777 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 90000 | 3 |
0.043 | 248000 | 2 |
0.044 | 114835 | 2 |
0.045 | 21740 | 1 |
0.046 | 40835 | 2 |
Last trade - 15.50pm 25/07/2025 (20 minute delay) ? |
Featured News
EMD (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online